Lester Rachael 4

What Happened

• Rachael Lester, Chief Business Officer of CytomX Therapeutics (CTMX), received equity awards on Feb 2, 2026 totaling 120,000 shares at $0.00 per share. The filing shows three grant lines: 20,000 restricted stock units (RSUs), a 50,000-share derivative award, and a 50,000-share derivative award — totaling 120,000 shares granted (all recorded as Code A — Award/Grant).
• These awards are not purchases or sales — they are compensation grants. No cash changed hands on grant; value will depend on future vesting and stock price.

Key Details

• Transaction date and price: 2026-02-02, $0.00 per share (grant).
• Grant breakdown (per filing/footnotes): 20,000 RSUs; a 50,000-share award that includes equity subject to monthly vesting; and a 50,000-share performance-based award. Total = 120,000 shares.
• Vesting/conditions (per footnotes):
  • F1: RSUs — 1/3 vest annually on March 15, starting March 15, 2027, subject to continued service.
  • F3: Option-like award — 1/48th vests monthly beginning Feb 2, 2026; fully vested after 4 years, subject to continued service.
  • F4: PSUs — each PSU vests (and becomes payable) 1/3 upon achievement of each of three clinical milestones, subject to continued service.
  • F2 notes one of the grant components “includes 20,000 RSUs” as described in the filing.
• Shares owned after transaction: not specified in the provided excerpt.
• Filing timeliness: Form 4 was filed Feb 4, 2026 for a Feb 2, 2026 grant — appears timely (Form 4 is due within two business days).

Context

• These are awards/long-term compensation, not open-market purchases or immediate sales. The option-style award vests over four years; the PSUs depend on clinical milestones, so actual shares received will depend on service and future milestone achievement. Such grants are common for executive compensation and do not by themselves indicate buying or selling sentiment.